statement
In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved a p-value.
A statement by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.
600mg 지속 투여군에서 p-value 달성
Discussion
Related claims
In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.report author · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementFrom year-end, the D2T RA approval direction will be discussed with the FDA, and GD (Phase 2b) and MG (Phase 3) top-line results are scheduled for 2027.하나증권 제약/바이오 김선아 · commitmentImmunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statement